Navigation Links
Therapy should extend beyond childhood
Date:7/29/2009

By systematically analysing MRI changes occuring in the brains of children with the metabolic disease glutaric aciduria type I researchers at Heidelberg University Hospital have succeeded for the first time in demonstrating reversible and permanent brain damage as well as elucidating its temporal evolution.

The Heidelberg researchers now assume that during the course of the disease, the products of metabolism cause not only acute, but chronic toxic damage as well. Therapy should thus be extended to prevent long-term brain damage.

These new insights enhance the understanding of the natural course of the disease and confirm the benefit and consequently the necessity of newborn screening for rare metabolic diseases and neonatal therapy. The study was published in the prestigious journal Brain.

Permanent damage when treatment is delayed

One of 100,000 newborns suffers from the rare metabolic disorder glutaric aciduria type I. Affected children are unable to break down certain amino acids (lysine, hydroxylysine, and tryptophan), which are components of proteins, but produce pathological metabolites that accumulate and can damage the developing brain.

Even before birth, brain changes indicating delayed development occur, which however are reversible if they receive adequate treatment in time. Permanent brain damage usually occurs in clinically inconspicuous babies if the diagnosis is not made in time and treatment is delayed.

Babies are initially free of symptoms / Severe crises during infancy and childhood

As newborns and young babies, the patients are initially inconspicuous. If not treated, they undergo a severe crisis at the age of 3 to 36 months. As the same deep regions of the brain are affected as in Huntington's disease, the children have similar movement disorders but their intelligence is usually spared by the neurodegenerative process.

However, the children's prognosis is favourable if the disease is detected early by newborn screening, which -using a drop of blood taken from the heel- is carried out in Germany for all newborns. The diagnosis after birth is the most important condition for successful treatment, i.e. normal development and prevention of irreversible cerebral injury. The therapy consists of a special diet low in the amino acid lysine, and supplemented with carnitine, an endogenous carrier for fatty acids, which is lost through urine in this disease. In addition, intensive emergency treatment of the metabolism must be carried out to prevent a metabolic crisis during febrile infections.

For their study, an international interdisciplinary research group of neuroradiologists and pediatricians headed by Dr. Stefan Klker from the Center for Pediatric and Youth Medicine and Dr. Inga Harting from the Department of Neuroradiology examined 38 patients from newborns to adulthood, comparing MRI changes with neurological symptoms and analyzing the time patterns.

Reversible and irreversible changes occur

They discovered that MRI changes in certain regions of the brain (e.g. in the white matter and cerebral cortex) occured frequently and in all patients, whereas changes in the basal ganglia occurred only in patients who had experienced encephalopathic crises. The changes outside of the basal ganglia were quite variable, some were reversible, and some were apparent as early as the neonatal stage and had no clinical significance. In contrast, the changes in the basal ganglia were irreversible and were clearly associated with the development of severe movement disorders.

The Heidelberg researchers now assume that during the course of the disease, the products of metabolism cause not only acute, but chronic toxic damage as well. Therapy should thus be extended to prevent long-term brain damage.

The Heidelberg researchers hypothesize that in the course of the disease, abnormally accumulating metabolites not only give rise to acute, but also to chronic toxic damage. For treatment purposes, this would mean that the duration of current therapy should be extended beyond childhood to prevent long-term changes and damage to the brain. This remains to be elucidated by follow-up studies.

Heidelberg Metabolism Center screens 100,000 newborns annually

Newborn screening in Germany is carried out to detect glutaric aciduria type I and 13 other diseases. The Metabolism Center of the Heidelberg Clinic for Pediatric and Youth Medicine carries out newborn screening for 100,000 newborns annually. The current guidelines in Germany and three other European countries for the diagnosis and therapy of children with this rare metabolic disease were compiled by an international guideline group headed by Dr. Klker. Parallel to this, the same working group carried out translational studies to examine new therapy approaches in a mouse model.


'/>"/>

Contact: Dr. med. Inga Harting
Inga.Harting@med.uni-heidelberg.de
062-215-67564
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. Carboxytherapy and Mesotherapy Unproven, Warns The Physicians Coalition for Injectable Safety
2. Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer
3. Northwest Hospital Introduces Hyperbaric Oxygen Therapy
4. Most Not Worried by Delayed Prostate Cancer Therapy
5. Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option
6. Xoft Expands Cancer Treatment Platform With Launch of Skin Cancer Electronic Brachytherapy Trial at AAPM Meeting
7. Cold Laser Technology Made Even More Accessible with Powerful New Product Available from Laser-Therapy.US
8. First Customer Installs CyberKnife System in Existing Radiation Therapy Vault
9. Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy Since Last Years Analysis of Prescribing Trends in Schizophrenia
10. Life after chemotherapy: Daily tasks, quality of life may be affected, MU researcher finds
11. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapy should extend beyond childhood
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad Kawa, ... eligible individuals in the local community. , Colon cancer is the second leading ... colon cancer while it is small, confined and easier to treat. If you are ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
(Date:3/29/2017)... Atlanta, Georgia (PRWEB) , ... March 29, 2017 , ... ... Theresa Therilus, founder of Pet Protect Law that assists dog owners in ... will assist new owners in taking the natural next step to protect their new ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC ... as the official title sponsor of the Baltimore Women’s Classic, the largest all women’s ... will walk or run the course around the Baltimore Inner Harbor. Mercy has been ...
(Date:3/29/2017)... ... , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of ... used for thousands of years. , "The West has caught on, and has discovered ... to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... , March 30, 2017  Lannett Company, Inc. (NYSE: ... voluntarily made a $25 million payment against its existing ... payment, combined with the $75 million payment we made ... $5.5 million in annualized cash interest expense, at current ... of Lannett.  "Our business is solid and we continue ...
(Date:3/30/2017)... Mar 30, 2017 Research and Markets ... Dialysis Market Size & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), ... Trend Analysis From 2014 To 2025" report to their ... ... to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... , March 29, 2017  Bodycad announced ... Drug Administration (FDA) 510(k) clearance for its Bodycad ... this truly personalized orthopaedic restoration. Bodycad is the ... a joint reconstruction implant system. ... optimize personalized restoration of the patient,s unique anatomical ...
Breaking Medicine Technology: